Rhythm Pharmaceuticals Inc

6 de nov. de 2026, 23:46 UTC

Rhythm Pharmaceuticals, Inc. is experiencing a slight decline in after-market trading, moving lower from a peak shortly after the market closed.

5 de nov. de 2026, 23:31 UTC

Rhythm Pharmaceuticals, Inc. shares are moving lower in after-market trading, reflecting a decline since Thursday's close amid broader market downturns.

4 de nov. de 2026, 23:02 UTC

AstraZeneca made a non-binding offer of about $10 billion to acquire Rhythm Pharmaceuticals, proposing $124 per share, according to The Wall Street Journal.

3 de nov. de 2026, 21:02 UTC

Rhythm Pharmaceuticals reports a Q3 net loss of $42.4 million, or $0.61 per share, exceeding revenue estimates but falling short of analyst expectations.

2 de nov. de 2026, 21:04 UTC

Rhythm Pharmaceuticals, Inc. shares are trading higher today, with notable volume and positioning above their 20-day moving average, despite an earlier pullback.

30 de out. de 2026, 20:08 UTC

Rhythm Pharmaceuticals shares are declining amid a broader downturn in the biotechnology sector, influenced by significant drops in the SPDR S&P Biotech ETF (XBI).

28 de out. de 2026, 20:07 UTC

Rhythm Pharmaceuticals shares are declining amid broader market volatility following the Federal Reserve's decision to maintain interest rates steady.

27 de out. de 2026, 20:07 UTC

Rhythm Pharmaceuticals, Inc. shares are advancing, supported by a broader rally in the biotechnology sector and gains in the SPDR S&P Biotech ETF (XBI).

22 de out. de 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares are advancing amid a significant upward movement in the Biotechnology sub-sector, gaining ground since Wednesday's close.

21 de out. de 2026, 19:46 UTC

Shares of Rhythm Pharmaceuticals Inc fell sharply, trading significantly below its 20-day moving average ahead of its Q3 2026 financial results announcement on November 3, 2026.

20 de out. de 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is trading higher in after-market hours, continuing a trend of three consecutive sessions that have also closed higher.

19 de out. de 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading on Monday.

15 de out. de 2026, 20:07 UTC

Rhythm Pharmaceuticals receives an Overweight rating from JPMorgan, with the price target adjusted to $145.00, reflecting a continued positive outlook.

14 de out. de 2026, 19:56 UTC

Rhythm Pharmaceuticals Inc launched IMCIVREE in Japan as the first approved therapy for acquired hypothalamic obesity, supported by Phase 3 TRANSCEND trial data.

13 de out. de 2026, 22:11 UTC

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading, correlating with slight gains in the Direxion Daily S&P Biotech Bull 3X ETF.

12 de out. de 2026, 19:46 UTC

Rhythm Pharmaceuticals Inc shares fell, fluctuating within a routine range and remaining significantly below its 20-day moving average.

9 de out. de 2026, 20:07 UTC

Rhythm Pharmaceuticals shares advanced after BofA set a new price target of $150, supported by positive feedback on its MC4R franchise for adult hypothalamic obesity.

8 de out. de 2026, 20:01 UTC

RBC Capital raises Rhythm Pharmaceuticals price target to $159.00 from $155.00 while maintaining an Outperform rating, citing strong market performance over five years.

7 de out. de 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, remaining well below their 20-day moving average and significantly lower compared to Tuesday's close.

6 de out. de 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving further below its 20-day moving average since Tuesday's close.

5 de out. de 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of six consecutive daily declines and remaining below its 20-day moving average.

2 de out. de 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions in the red and remaining below the 20-day moving average.

1 de out. de 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is advancing in after-market trading, gaining ground since Thursday's close while currently trading below its 20-day moving average.

29 de set. de 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, declining notably from Monday's close and trading well below its 20-day moving average amid ongoing pressure.

24 de set. de 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell modestly, currently near the lower end of their one-month range and below the 20-day moving average amid broader market weakness.

23 de set. de 2026, 22:25 UTC

Rhythm Pharmaceuticals Inc is rising in after-market trading, recovering from an initial dip and advancing since Wednesday's close, though still below its 20-day moving average.

22 de set. de 2026, 20:07 UTC

Rhythm Pharmaceuticals' IMCIVREE® received Health Canada approval for weight management in patients with acquired hypothalamic obesity, boosting shares higher during the session.

21 de set. de 2026, 20:06 UTC

Rhythm Pharmaceuticals Inc is higher today, continuing an upward trend since Friday, despite mid-morning volatility and remaining below its 20-day moving average.

18 de set. de 2026, 20:06 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, settling near the lower end of their one-month range and significantly below the 20-day moving average.

17 de set. de 2026, 20:07 UTC

Rhythm Pharmaceuticals advances during Thursday's session, boosted by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.